Immedica Pharma AB entered a merger agreement on December 30, 2024, to acquire Marinus Pharmaceuticals, Inc. (MRNS) through a tender offer of about $151 million.
Under the terms of the agreement, Immedica, through a wholly owned, direct subsidiary, will initiate a tender offer to acquire all the outstanding shares of Marinus common stock for a cash purchase price of $0.55 per share, representing a premium of 48.65% from the stock’s last close.